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Abstract
Background: A large number of stakeholders have accepted the need for greater transparency in clinical
research and, in the context of various initiatives and systems, have developed a diverse and expanding
number of repositories for storing the data and documents created by clinical studies (collectively known
as data objects). To make the best use of such resources, we assert that it is also necessary for stakeholders
to agree and deploy a simple, consistent metadata scheme.
Methods: The relevant data objects and their likely storage are described, and the requirements for metadata to
support data sharing in clinical research are identified. Issues concerning persistent identifiers, for both studies and
data objects, are explored.
Results: A scheme is proposed that is based on the DataCite standard, with extensions to cover the needs of
clinical researchers, specifically to provide (a) study identification data, including links to clinical trial registries;
(b) data object characteristics and identifiers; and (c) data covering location, ownership and access to the
data object. The components of the metadata scheme are described.
Conclusions: The metadata schema is proposed as a natural extension of a widely agreed standard to fill
a gap not tackled by other standards related to clinical research (e.g., Clinical Data Interchange Standards
Consortium, Biomedical Research Integrated Domain Group). The proposal could be integrated with, but is
not dependent on, other moves to better structure data in clinical research.
Keywords: Metadata, Standards, Data sharing, Transparency, Data repositories, Identifiers, European Clinical
Research Infrastructure Network, ECRIN
Background
Recent years have seen a welcome push towards greater
transparency in clinical research. The first stage saw the
drive, initially from journal editors, for the prospective
registration of clinical trials [1]. The second has been the
increasing pressure to publish results from all trials, at
least in summary form, as exemplified by the All Trials
campaign [2], as endorsed by the World Health Organ-
isation (WHO) [3] and as facilitated by ClincalTrials.gov
[4] and, in the near future, by the new European clinical
trial portal [5].
But, as Vickers has recently described [6], there is an
increasing consensus that a third element is required for
full transparency – the source data itself, the individual
participant records – so that, for example, analyses can
be re-run using different methods, or secondary analyses
applied, or data aggregated with that of other studies to
generate more powerful meta-analyses [7–10]. But ‘raw
data’ can be misleading in isolation. To fully understand
the source data and the results derived from it, it is also
necessary to have access to other study documents, such
as protocols, clinical study reports, analysis plans and
case report forms.
So, true transparency requires the availability of a wide
range of clinical trial ‘data objects’, to use the generic
term for anything available in an electronic format.
These include published documents, documents that
traditionally are private and seen only by the trial team,
data sets representing summaries of results, and data
sets representing the full source data. The assumption is
not that all of these documents should necessarily be
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made public, but that, subject to proper governance and
the protection of individual participant privacy, they
should be made available to bona fide researchers who
can provide good reasons for requesting access.
There is now very broad support for these ideas.
Several major journals require a statement from au-
thors describing their plans for data sharing [11–13].
Many funders also require a commitment to data
sharing [14–16]. The pharmaceutical industry has
made a public commitment to clinical trial data shar-
ing [17], and initiatives such as the Yale Open Data
Access (‘YODA’) [18] and Clinical Study Data Request
(CSDR) [19] schemes provide a mechanism for re-
searchers to submit requests for anonymised data to
several drug companies. A key development has been
the 2016 proposal from the International Committee
of Medical Journal Editors, which stated that authors
should be required ‘to share with others the de-
identified individual-patient data (IPD) underlying the
results presented’ [20] page 1.
A host of different data repositories have been devel-
oped to help support data-sharing initiatives. Some of
these are generic, such as Datadryad [21] (recommended
by the British Medical Journal [BMJ]), Zenodo [22] and
the Dataverse Project [23]. Others are focused on par-
ticular disease areas, such as National Institute on Drug
Abuse Data Share [24] for drug abuse trials and the
National Database for Clinical Trials Related to Mental
Illness [25], both in the United States, or the global
Repository of Registered Migraine Trials [26]. A generic
clinical trial data repository, for both academic and com-
mercial users, is planned by the Multi-Regional Clinical
Trials Unit (MRCT) at Harvard University [27], whilst
the OpenTrials initiative, though mostly focused on
metadata, is also planning to host original study data
and documents when necessary [28]. These systems are
in addition to the company-specific repositories already
in existence, an increasing number of institution-specific
data repositories that can store data objects relating to
clinical research (e.g., at the University of Edinburgh
[29] and the University of Nottingham [30] in the United
Kingdom), and the more ‘traditional’ data repositories of
clinical research material – the various publisher sites
which allow access to peer-reviewed journal papers.
This does not take into account the range of material
relating to clinical research, documents as well as data,
that could potentially be flagged as ‘available on request’
but not moved to a designated repository at all – just
stored within the systems of the original research team
or department. For convenience, in this paper, the term
repository is used to include both dedicated data and
document storage facilities, explicitly labelled as a reposi-
tory, and the information technology (IT) infrastructures
used for long-term storage within an institution, when
the stored material includes data objects that have been
listed as potentially available to others.
As the acceptance of the need for data sharing in-
creases, this mosaic of repositories seems likely to be-
come more complex, even allowing for periodic
attempts at collaboration or aggregation. Data and docu-
ments will therefore be split between a wide variety of
repositories and storage locations, many specialised and
serving particular research communities, geographic
areas, or institutions, even if a few larger, more generic
repositories do emerge. The files themselves are likely to
be in a wide variety of different formats and file types.
Gathering the relevant data, papers and documents
together, in the context of a particular study or review,
even identifying what is available and under what
arrangements, risks becoming difficult, time-consuming
and expensive.
Methods
Types of data objects
There is a very wide variety of ‘data objects’ that can be
generated by or linked with a clinical research study,
especially a clinical trial. They include the following:
 Before the trial begins: A protocol, funding
applications, applications for ethical and regulatory
approval, registry data sets, patient information
sheets, consent forms, statistical analysis plan(s), a
data management plan, treatment allocation plans,
paper and electronic case report forms, training
materials for staff, and contracts with clinical sites.
 During the trial: Amended versions of the protocol,
amended versions of consent forms and the like,
interim data sets (e.g., for safety analysis), treatment
allocation records, site monitoring reports, websites
and newsletters with information for the public and
participants.
 As the trial ends: Final data sets for analysis,
including subsets for sub-study or secondary
endpoint analysis, a clinical study report, registry
results sets, press releases, published posters,
presentations and journal papers.
 After the trial is complete: Long-term follow-up
data sets and papers, reviews and meta-analyses,
re-analyses, methodological reviews, editorials and
comments.
Not all of these are necessarily relevant to the primary
analysis and conclusions of a study, but they can all con-
tribute to a full understanding of the research, and, even
if many are not normally public, they could all poten-
tially be requested by other researchers.
The guiding principles for findable, accessible, inter-
operable and reusable data (the FAIR principles) [31]
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explain how, to be useful in a data-sharing context,
any data object needs to have two additional proper-
ties: (a) a unique persistent identifier (PID) and (b)
metadata that describes the object. The metadata is
split between that which is permanent and intrinsic
to the object, and that which is a function of its loca-
tion and history, which could therefore differ over
time (see Fig. 1).
For example, a published study protocol will probably
have a digital object identifier (DOI) assigned – its PID
– and the data element will be the.pdf document file
itself. The associated intrinsic metadata will include the
protocol title, version, authors and creation date,
whereas the provenance metadata will include its uni-
form resource locator (URL), the organisation (pub-
lisher) hosting the document, and the accessibility
regime (in this case ‘public’).
A data set made available for sharing will also need a
unique identifier assigned (perhaps a DOI, perhaps a
local identifier guaranteed unique by combining it with a
web address), and the intrinsic metadata will need to
unambiguously identify the source study, as well as
the date and type of the data set. It should also refer-
ence the data object (e.g., an associated Clinical Data
Interchange Standards Consortium [CDISC] oper-
ational data model [ODM] file) that contains the
metadata describing the data object’s contents (which
of course is distinct from the metadata describing the
data object itself ). The provenance metadata will
again need to include the organisation currently host-
ing the data, and the accessibility type. If, as is likely
to be the case, access is restricted, there will be no
direct link to the document, but there should be
some indication of how access might be gained (e.g.,
a URL to a website that holds details of the applica-
tion process).
A metadata proposal
A human being or a machine that wishes to identify,
catalogue, search for and access a data object will need
to make use of that object’s PID and the metadata.
Making the best use of available clinical research data
objects, given the wide variety of different repositories
described above, is therefore dependent on those data
objects’ having generally understood PID and metadata
properties, and then reading those properties. The easi-
est way of simplifying that process is to have all the
repositories describe their content in the same way – to
develop and apply a common metadata schema for clin-
ical research data objects.
With a common metadata scheme, systems can effi-
ciently examine and index the data objects being stored,
creating an aggregated catalogue of content across a
range of related repositories (or, most ambitiously, a
global catalogue across all of them). This would allow
the data objects available for any study to be more easily
discovered and to be described in sufficient detail for
potential users to decide whether they wished to access
them, or at least apply to access them.
Exactly how the metadata is organised may vary – it
could be, for example, an extensible markup language
(XML) file; a JavaScript object notation (JSON) file; a
text document; or held within the data structures of a
relational, graph or document database. Nor is there any
assumption about how and where the metadata will be
stored relative to the source data objects themselves. For
instance, it could be in separate files stored alongside
the data objects, as embedded tags in human-readable
indexes of the repositories, within databases made avail-
able via an application programming interface (API), as
SPARQL Protocol and RDF Query Language endpoints,
or even as part of the metadata ‘injected’ into a docu-
ment as can be done, for example, with .pdf files. The
important point is that the data points within the
schema should be consistent so that the metadata can
be easily aggregated and compared, and the information
within it extracted.
What should a metadata scheme for clinical re-
search objects include? The metadata would normally
need to be provided by the ‘owners’ of the data ob-
jects (i.e., those making them available for public or
managed access). It should therefore be as simple and
represent as light an administrative burden as pos-
sible; however, given the nature of clinical research
data objects and the use cases to which such data will
be put, we believe the metadata must support three
main tasks:
Fig. 1 A data object’s structure (From [31].). PID Persistent identifier
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1. Metadata should unambiguously identify the
research study that the data object is about
(or generated from or used within). Some data
objects, such as meta-analysis documents and
data sets, may refer to more than one study.
2. Metadata should characterise the research object
itself – for example, its type, authorship, contents,
size and language.
3. Metadata should describe where the object can be
found and the access regime under which the data
object is available. If not public, the regime needs to
be described in sufficient detail for a potential user
to be able to proceed with applying for access.
Note that the intended scope of this scheme is all
types of protocol-driven clinical research (i.e., non-
interventional studies as well as clinical trials). This is
not to deny the prime importance of trials as generating
the best-quality evidence, nor the fact that most of the
current efforts to increase transparency are focused on
clinical trials. It is simply that any metadata scheme
should be flexible enough to include references to other
types of research (e.g., observational, translational, using
biobank data). Having a general structure in use from
the beginning will be much easier than trying to adapt a
more specific one later.
Identifying the study
It would seem straightforward to describe metadata that
could unambiguously identify the study or studies that a
data object was ‘about’, but in fact there is no universal,
consistent and PID scheme available for clinical research
studies. There are various options available, but none of
them are truly comprehensive. The following are some
of the candidate study identifiers:
 Registry identifiers (IDs): Most (but not all) clinical
trials are entered prospectively into publicly
accessible trial registries such as ClinicalTrials.gov.
That provides them with a PID that is unique when
coupled with an identifier for the registry (normally
its URL or an abbreviation). But trials may have two
or more such registry entries, and there is often no
sense in which one is the ‘prime’ or ‘canonical’
identifier. Different people and different systems
will therefore refer to a study using different registry
IDs. In addition, even now, 10 years after the
original decree from the International Committee
of Medical Journal Editors [1] that they would not
publish trial results without prior registration, a
large proportion of smaller journals are still not
requiring registration [32], and nearly 12% of a
recent sample of published mental health trials were
unregistered, along with 33% that were
retrospectively registered [33]. Nevertheless, registry
IDs are probably the best way currently available to
identify clinical trials. Unfortunately, despite much
debate about the merits of registering observational
studies, only a small proportion of such studies are
currently registered, and even then registration is
rarely prospective [34].
 The Universal Trial Number: The WHO, aware of
the issues of multiple registry IDs, has introduced
a Universal Trial Number, or ‘UTN’ [35], but the
use of this appears to be relatively limited at the
moment, and it still applies only to studies that
appear in registries.
 Protocol title: Though textual rather than an ID,
all studies should have a protocol, which will have
a long or ‘scientific’ title of the study on its cover.
The difficulty is that the title cannot be guaranteed
to be unique (unless combined with some other data
– e.g., creation year, sponsor name), and it may vary
slightly between different uses, such as between
different versions of the protocol document.
 Ethics identifier: Although not all studies are
registered, all studies involving people (or samples
derived from living people) require ethical approval.
As part of the approval process, studies almost
always acquire an identifier in the ethics system.
Making these identifiers accessible, and combining
them with a URL for the organisation assigning
them, would again provide a unique ID for the
study. (If multiple ethics applications were required,
then only the first need be used.) The difficulty is
that this information is usually not public, so such
a scheme could not be used now. It is mentioned
because it is one of the few mechanisms that
potentially could provide a universal index of clinical
studies.
In practical terms, almost all studies will have
multiple identifiers associated with them – some
public, such as registry IDs and the identifiers
assigned by regulatory authorities, and others in-
ternal, such as the IDs used by sponsors and fun-
ders. The best way to uniquely identify the study
linked to a data object would seem to be to use the
protocol title combined with whatever public identi-
fiers are available. That data would be available to
the data object ‘owners’, and it seems reasonable to
expect it to be included in the associated metadata
description of that object.
Identifying the data object
Data objects published publicly (e.g., journal articles,
plus some data sets and protocols in repositories) will
normally already have a DOI. We propose that all
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publicly available clinical research data objects should
have a DOI assigned, so that they have a unique
identifier.
The difficulty relates to non-public data objects.
We propose that, wherever possible, these data ob-
jects should also have a DOI. In particular, we would
like to see DOI assignment as an integral, mandated
component of the transfer process of a data object
to a designated repository, even if access to the ob-
ject was tightly controlled (including the scenario
where the repository was institution- or company-
specific). In other words, once the decision is taken
to make a data object available for sharing, a DOI
should be assigned, probably most easily by the ori-
ginal data-generating organisation. That implies an
extension of current DOI use, and the process would
need to be cheap and simple enough to make such
assignment feasible. But it would allow any data
object reference to be formulated in a consistent,
unambiguous and machine-readable way, and it
would provide a unique identifier for all the data
objects in repositories.
But we recognise that such a development may take
time and may never be applicable to all potential data
objects – for instance, those still retained by the source
organisation, not in a designated repository but simply
in long-term storage. We therefore recommend but do
not mandate a DOI for non-public data objects, because
we would not like to see the need for (and the potential
costs of ) DOI assignment reduce the amount of material
potentially available.
If a DOI is the preferred identifier but cannot be guar-
anteed, then the data objects will need to be identified in
some other way. One approach would be to use an in-
ternal (accession) ID from a comprehensive metadata re-
pository system, or from a confederation of such
systems, that listed all the data objects known to be
available. This is probably the simplest solution, though
it obviously would need such metadata stores to be
developed, and it introduces yet another identifier, one
that would have little meaning outside the metadata
repositories themselves.
A more natural approach would be to use the data
object’s title, but because this will often be generic (e.g.,
‘analysis data set’, ‘patient information sheet v1’), it will
be necessary to combine the title with a study identifier
to generate a unique identifier for the object (e.g.,
‘NCT02258999\patient information sheet v1’). Unfortu-
nately, as discussed above, there is no consistent and
universally applicable method for generating a study
identifier. This approach would therefore depend on first
distilling and applying a universally recognised scheme
for a study ID, using one of the methods already
described.
We will therefore need to take a pragmatic approach in
generating and assigning identifiers – for example,
developing business rules that use particular identification
methods in a set order, to both studies and data objects,
until one of them gives a useful identifier. Both data object
and study identifiers will also always need to be a compos-
ite, indicating their type and source as well as their value.
Results
The scheme we propose is summarised by Table 1. It
is based on the existing DataCite scheme for charac-
terising data objects. (The reasons for this choice are
given in the Discussion section below.) The portion
of the table labelled B–E consists of intrinsic meta-
data that can be mapped to the DataCite scheme,
whereas sections A and F represent proposed exten-
sions to that scheme.
Additional file 1 provides a more formal description of
the proposed scheme and also highlights its inter-
relationship with the DataCite schema. That inter-
relationship is summarised in Additional file 2, whilst
Additional file 3 shows how the mandatory and recom-
mended fields in DataCite are treated within this pro-
posal. The sections below describe the proposed
scheme’s major features, using the same section headings
as given in Table 1.
A. The source study or studies
The proposal is that, for each study associated with a
data object, the following data points are defined:
Table 1 Elements in the proposed metadata scheme for clinical
research data objects
Mandatory Recommended Optional









C.1 Creatorsa C.2 Contributorsa
D.1 Creation year D.2 Datesa








F.4 Access details (2)





DOI Digital object identifier
(1) Mandatory for publicly accessible data objects, recommended for all others
(2) Mandatory if access is non-public
aMay be repeating
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A.1 Source study title (1)
The source study title is the name of the study or
studies that the data object describes, was generated by,
and/or refers to (but not those it simply cites). The
‘name’ in this instance means the full or ‘scientific’ title
(i.e., the title of the study protocol). For the sake of
consistency, it should be the exact title as used on
version 1.0 of the protocol.
A.2 Study identifier records (0…n)
The study identifier comprises none, one or more
unique identifiers that have been assigned. There is no
assumption that a study will have an identifier of a
particular type. For studies entered into trial registries,
these should include, at minimum, the registry ID(s),
but any IDs that have been externally applied and
that might be useful in identifying the study can be
included. These IDs are composite. If provided, they
must include not just the identifier value and type but
also the assigning organisation, the scheme uniform
resource identifier (URI) if there is one, and optionally
the date the identifier was assigned (see Additional
file 1). (Options used for identifier type and assigning
organisation could be common with the lists used for
DOIs, as described in B.2 below).
A.3 Study topics (0…n)
The study topics comprise none, one or more topic
names or phrases, keywords, or classification codes
describing the study or aspects of it. Topics is
preferred to subjects because ‘Study subjects’ is
normally understood as referring to the study
participants. In the context of clinical research data
objects, it makes sense to include any topic data
with the study rather than the individual data
objects relating to that study.
The listed topics could be free text, but it would be
more useful if the text were structured (i.e., selected
from a controlled vocabulary). There are a variety of
such controlled vocabularies available for studies. Some
refer to just a few data points, such as the International
Classification of Diseases, Tenth Revision, for indicating
the disease area that was the subject of the study, or
Anatomical Therapeutic Chemical Classification System
(ATC) categories for indicating the type of drug(s) used.
More general ‘study ontologies’ are also available, such
as The Cochrane Collaboration PICO ontology (patient/
population/problem, intervention, comparison, outcome)
[36] and, from the Biobank community, a set of study
descriptors included in Minimum Information About
Biobank Data Sharing ((MIABIS) [37]. There is also the
Clinical Trial Registry (CTR) schema from CDISC, spe-
cifically designed to support trial registry data sets [38],
which may therefore be a useful source of topic terms.
To ensure that the source system is clearly identified,
any use of a controlled vocabulary term should be
associated with a URI that identifies the scheme (and
version) being used.
Although topic data have enormous potential value in
identifying related studies, in these proposals it is not
mandatory. Apart from the present confusing plethora
of options, there is also the problem that extracting such
data retrospectively can be expensive and error-prone if
not done by those most familiar with the study. One
could also argue that a registry identifier, for instance,
would allow the user to discover information about the
study by looking up the registry data set.
In the longer term, use of more structured and con-
sistent protocols (e.g., with CDISC CTR embedded in
the Standard Protocol Items: Recommendations for
Interventional Trials (‘SPIRIT’) guidelines [39]) would
allow easier and more accurate extraction of structured
data about studies, but we do not yet have the tools to
support protocol construction in this way. If and when
such tools are developed and their use becomes more
common, it might be possible to mandate ‘study topic’
data of particular types, considerably enriching the meta-
data available.
B–E. Data object characteristics and object identifiers
Sections B–E are heavily based on the current DataCite
metadata specification [40] and so are dealt with rela-
tively briefly.
B.1 Data object identifier
Data objects available publicly, such as journal articles,
plus some of the data sets and protocols in repositories,
should have a DOI (in line with the DataCite specifica-
tion). As discussed in the Methods section above, non-
public data objects should also, wherever possible, also
have a DOI. If a DOI is not possible, or has not yet been
assigned, then the object should be identified either by
an accession number from a metadata repository system
or by using the object’s name and version code, coupled
with a unique identifier for the source study. The data
object identifier (like study identifiers) therefore needs
to be a composite, indicating its type and source as well
as its value.
B.2 Other object identifiers
‘Other object identifiers’ refers to other unique identi-
fiers that have been assigned to the data object in
addition to its primary identifier. Again, such IDs would
be composite and include the identifier type and assign-
ing organisation, as well as its value, and optionally the
identifier scheme and date of assignment. The lists used
for identifier type and assigning organisation could be
common with the lists used for study identifiers.
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B.3 Object title and B.4 Additional titles
Within the context of the associated study or studies,
the default name of the data object should be unique.
Additional names can also be provided. If given, they are
composite: the title plus one of ‘title type’ (e.g., trans-
lated title, alternative title, subtitle).
B.5 Version
Optionally, the version code for the data object is used.
Many versions of a particular data set or document may
have been created in the course of a clinical study, but
the focus here is on the version or versions that are
made available for sharing. The data generators will need
to make that selection, though the normal expectation
would be that the final version of a data object (e.g., a
protocol) would be the one that was shared with others.
In some cases, multiple versions of the same docu-
ment or data set could be made available, or they might
be specifically requested. For instance, data sets used for
the primary analysis should normally be available, as well
as possible later data sets that have additional follow-up
data. A protocol published before the trial began may
need to be differentiated from the protocol as it existed
at study end. Assuming the data objects have similar
names, they will therefore need to be clearly differenti-
ated using version codes (and relevant dates [see D.2
below] and possibly descriptions [see E.3 below]). E.6
describes how the relationship to previous or next ver-
sions can be made explicit. The form of the version cod-
ing would be as created and applied by the data
generators.
C.1 Creators
The creators are the main personnel involved in produ-
cing the data, or the authors of a publication. It may be
a set of institutional or personal names. Each name in
the list is a composite element and can contain optional
identifiers (e.g., Open Researcher Contributor Identifica-
tion [‘ORCID’] identifiers and/or organisational affilia-
tions, as well as the name itself ).
C.2 Contributors
Optionally, other institutions and/or persons responsible
for collecting, managing, distributing or otherwise con-
tributing to the development of the data object can be
included. If given, any contributor record is composite,
with the same structure as the Creator data above, plus
an additional data point specifying contributor type. The
latter may need extending in the context of clinical
research to include, for example, drug supplier, drug
distributor, device manufacturer, central laboratory,
sponsor contact, recruitment contact, principal and chief
(or co-ordinating) investigator.
D.1 Creation year
The creation year is the year in which the object was
created, expressed as four digits. Its precise definition
will vary with the nature of the data object. For data sets,
it will be the year of their extraction; for published docu-
ments, the year of their initial publication; and for in-
ternal documents, the year of their approval for use.
Note that ‘creation year’ is intended only to provide an
indicator of the time something was created (e.g., in an
on-screen listing). It is not a date, which is collected and
stored separately (see D.2 below).
D.2 Dates
None, one or more dates or date ranges that are relevant
to the data object, in the standard ISO 8601 format, are
used. Each date should be accompanied by a date type
value that indicates what the date represents, such as ac-
cepted, available, copyrighted, collected, created, issued,
submitted, updated, valid. This list (from DataCite) may
need extending to better span the clinical research
domain.
E.1 Resource type general
Resource type is one of the existing DataCite controlled
list. In most cases, for clinical research data objects, the
type will be ‘text’ or ‘data set’.
E.2 Resource type
Resource type is a description of the resource. The for-
mat is open, but the preferred format is a single term, so
that a pair can be formed with the ‘resource type gen-
eral’ described above (e.g., data set/census data or text/
conference abstract). Existing types will need extending
by a list of standard resource types for clinical research
(e.g., protocol, patient information sheet, final analysis
data set, quality of life data set). In practice, an expand-
able list would be needed (i.e., one where a user could
supplement the supplied controlled vocabulary terms by
free text, as and when necessary).
E.3 Description
The description comprises none, one or more pieces of
additional general information. The format is open, but
any description should be accompanied by a description
type to further characterise the data: one of abstract,
methods, series information, table of contents, other.
E.4 Subjects
Subjects comprise none, one or more subject names or
phrases, keywords, classification codes describing the re-
source. In general, however, the recommendation is to
include any subject or topic descriptors, keywords, and
so forth, with the study data rather than the individual
data objects (see A.3 above).
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E.5 Language
The language is the primary language of the resource,
using the International Organisation for Standardisation
(ISO) language codes (e.g., EN, DE, FR).
E.6 Related identifiers
Related identifiers are the identifiers of related resources,
which must be globally unique identifiers. Related
resources will normally be data objects themselves. The
record is composite and must include the identifier
itself, the related identifier type and the relation type.
Relation types include IsCitedBy, Cites, IsSupplementTo,
IsSupplementedBy, IsContinuedBy, Continues, IsNew-
VersionOf, IsPreviousVersionOf, IsPartOf, HasPart,
IsIdenticalTo, IsDerivedFrom and IsSourceOf.
A particularly important relationship for clinical study
data is the pairing of HasMetadata-IsMetadata. Metadata
in clinical research can include, for example, an ODM
file or data dictionary that provides the metadata for a
data set. The metadata in this context is itself a file, and
as a data object in its own right, it is a ‘study data meta-
data data object’. This is quite distinct from the type of
metadata used to describe it and all the other documents
and data sets, as a data object, which is ‘data object
metadata’.
F. Identifying location, ownership and access
The other area where the existing DataCite schema
needs to be extended is in providing a full description of
the access arrangements for any data object. The follow-
ing data points are proposed.
F.1 Publisher
In this schema, this is the organisation that manages
access to the document, including making the overall
decision about access type (see F.3). For data, this would
be the name of the organisation managing the reposi-
tory. For journal papers, it is the name of the company
that publishes the journal and which would normally
run the primary website on which it can be accessed.
F.2 Other hosting institutions
Other hosting institutions are any organisations other
than the publisher identified in F.1 that also host the
data object within their IT infrastructure.
F.3 Access type
Access type is one of ‘public download’, ‘public on-screen
access’, ‘restricted download’, ‘restricted on-screen access’,
‘case-by-case download’ or ‘case-by-case on-screen ac-
cess’. Restricted means access would be dependent on
membership of a predefined group, usually as deter-
mined by an authentication mechanism (e.g., username
with password), such as is the case with subscription to
a journal. Case-by-case means that there is no prede-
fined access, but that applications for access to the data
object will be considered by the object owners. On-
screen access means that a researcher can view and
process data within a specified environment but cannot
download a file of the raw data, though export of the
results of re-analysis would be allowed.
F.4 Access details (mandatory for any of the non-public
access types)
Access details refers to a textual description of the access
being offered, such as identifying the groups to which
access is granted, the criteria on the basis of which a
case-by-case decision would be based, or any further re-
strictions on on-screen access.
F.5 Access contact (mandatory for any of the non-public
access types)
Access contact is a link to a resource that explains how
access may be gained, such as how a group can be
joined, and/or how application can be made for access
on an individual basis. This could include an email ad-
dress but more normally would be a link to a web page
on the publisher’s site that would explain access proce-
dures or provide an application pro forma.
F.6 Resources
Resources comprise the web-based resources that repre-
sent this data object. This is mandatory for public or re-
stricted access objects when at least one resource should
be listed. Each record would be composite and include
the F.6.1 resource URL and, if downloadable, the F.6.2
resource file type (e.g., file extension or Multipurpose
Internet Mail Extension [‘MIME’] type) and the F.6.3
resource size, usually in kilobytes or megabytes. The
resource host would usually be obvious from the URL.
F.7 Rights
Rights include any intellectual property rights information
for the data object, as a textual statement of the rights
management associated with the resource. The URI for the
specific rights management should also be given (F.7.1).
Discussion
In constructing this proposal, we first considered the
needs of potential users of any metadata scheme and
then examined various existing models and metadata
schemas to see if any current scheme could be used or
adapted – ideally one that was already widely accepted
and relatively simple to use. The difficulty is that while
clinical research has generated various standards and
metadata schemas, most of those are focused on the
events and entities within the research process rather
than on the documents and data generated by that
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process. For example, the CDISC has developed a range
of standards allowing different types of data sets to be
published in standardised formats [41], but these are
focused on the data set’s contents rather than on the
data sets themselves. Extensive conceptual models of
protocol-based research have been developed within the
Health Level 7 Reference Information Model (HL7 RIM)
[42] and Biomedical Research Integrated Domain Group
(BRIDG) [43] projects to facilitate interoperability be-
tween systems, but these are both highly complex and
focused on the research and its regulation rather than
on straightforward descriptions of its outputs.
The Organization for the Advancement of Structured
Information Standards has developed standards for the
component parts of electronic trial master files (eTMFs)
[44], and while these do include data object properties
and include a content classification scheme, it seemed to
us too specifically targeted at the details of eTMF com-
ponents to provide a general schema.
We also looked at more general metadata schemes for
data objects, including the Dublin Core Metadata Initia-
tive [45], the Data Documentation Initiative (DDI) [46]
and DataCite [40]. The DDI schema is focused more on
social sciences and the humanities than on clinical re-
search. The Dublin Core schema is very well established,
but we found that the most directly relevant scheme for
our purpose was DataCite (and there are proposals to
map DataCite onto the Dublin Core scheme in any case
[47]). DataCite is already in widespread use, with the
organisation listing over 30 members, including the Brit-
ish Library, the German National Library of Medicine,
the Harvard University Library, the Institute of Electrical
and Electronic Engineers and the Conseil Européen pour
la Recherche Nucléaire [48]. Its stated purpose is to de-
velop and support methods to locate, identify and cite
data and other research objects. It therefore seemed
most appropriate that the description of the data object
itself be handled by the DataCite scheme, albeit with a
slightly different emphasis on some components, and an
extension of some part of the controlled vocabulary, to
reflect the nature of data objects in clinical research.
It was then necessary to provide two logical extensions
to DataCite to cover (a) the identification of the source
study or studies and (b) the location, ownership and
especially the nature of access to the data object, given
that restricted access regimes are likely to be much more
common than public access. These extensions are as
described above in sections A and F in the Results section.
To keep the metadata definition as simple as possible,
and focused on describing the data object, the proposed
scheme requires identifiers only for the source study (or
studies), such as the title and public identifiers like regis-
try IDs. It is ‘agnostic’ about any additional study attri-
butes or descriptors, such as methodology type,
participant number, sponsor, location, chief investigator
and start date. Such information could be extremely use-
ful, and the scheme does allow for its inclusion (under
A.3: Study topics above), but it does not prescribe its
form. There are several reasons for this, outlined below:
1. There is no set of core attributes which by common
agreement would be seen as required for all studies.
The repositories being developed (e.g., the MRCT
[27] and OpenTrials systems [28]) intend to list
different, if overlapping, elements about the studies
generating the data objects, and the same is true of
different trial registries, though here at least there is
a core set of 20 items specified by the WHO [49].
2. Study attributes are often not available as structured
data (instead being buried within the text of
protocols, and even in registry entries simply cut
and pasted from there), and sometimes they are not
even assigned consistently in different systems.
Trying to extract, and then if necessary identify
amongst different candidates, the correct attribute
value can incur substantial time, effort and cost.
Prospective assignment of more structured data by
the researchers themselves could solve this problem,
but at present the tools to support this are missing.
3. Study attributes that may be important for one type
of study may not be relevant to another. Metadata
for a medical device trial’s data objects could usefully
indicate the type of the device(s) being tested, but this
would obviously not be relevant to other types of
studies. Defining a ‘core data set’ risks restricting data
points to that core, when other attributes might be
more significant in particular study types.
4. In most cases, at least for registered trials, registry
IDs would allow navigation to a source of more
detailed information about the study.
Any study attributes included would therefore be up
to the metadata creators. This ensures that the proposed
scheme is entirely compatible with the wide variety of
systems already in existence or being developed. Having
said all of that, if a particular set of study descriptor data
points were to become widely available (perhaps based
on the WHO core data set), it would seem wasteful not
to include them in the metadata schema, as long as this
did not inhibit additional attributes being added for par-
ticular types of studies.
A variety of tools could be envisaged that would allow
the application of the proposed schema once an object
was identified as being available for sharing, reducing
the costs of creating and harvesting the metadata, better
supporting the identification of relevant data objects,
and thereby better promoting the overall goal of greater
transparency in research. For instance, a web-based tool
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that prompted users for the relevant data and provided
sensible choices from drop-down lists (extensible where
necessary) would not only allow metadata to be created
more easily but also could automatically transfer that
data into storage. Linked to a generic ‘metadata reposi-
tory’, it could generate both a local and a central, public
metadata record, removing the need to harvest the infor-
mation using API interrogation or file import.
Conclusions
The proposed metadata scheme is an attempt to define a
basic data set that is applicable to all data objects related
to clinical research and addresses the need to explicitly
identify the access arrangements that will apply to many
of those data objects, as well as to unambiguously identify
the source study. It is a relatively simple extension of a
widely used existing scheme, DataCite, and is designed to
be used as a foundation for implementing systems for dis-
covering and indexing clinical research data objects. There
are particular difficulties in providing unique identifiers
for both the data objects and the studies with which they
are linked, but these are not insurmountable. These pro-
posals are made with the intention of initiating a debate
amongst interested stakeholders, with the aim of develop-
ing a consensus on a metadata scheme that can be used
throughout the clinical research community.
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